Profile data is unavailable for this security.
About the company
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
- Revenue in USD (TTM)0.00
- Net income in USD-16.24m
- Incorporated2016
- Employees4.00
- Location180 Life Sciences Corp3000 El Camino Real, Bldg 4, Ste 200PALO ALTO 94306United StatesUSA
- Phone+1 (650) 507-0669
- Fax+1 (302) 636-5454
- Websitehttps://180lifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sativus Tech Corp | 0.00 | -68.00k | 1.35m | -- | -- | -- | -- | -- | -0.0483 | -0.0483 | 0.00 | -0.5238 | 0.00 | -- | -- | -- | -18.83 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.41 | -- | -- | -- | 78.78 | -- | -- | -- |
Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 1.36m | 339.00 | -- | 0.016 | -- | 0.0453 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
LadRx Corp | 0.00 | 1.66m | 1.37m | 2.00 | 0.8014 | 3.96 | 0.8170 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
Nexien Biopharma Inc | 0.00 | -246.18k | 1.38m | 0.00 | -- | -- | -- | -- | -0.0038 | -0.0038 | 0.00 | -0.0048 | 0.00 | -- | -- | -- | -679.40 | -860.53 | -- | -1,653.53 | -- | -- | -- | -- | -- | -1.77 | -- | -- | -- | -- | 42.22 | -- | -- | -- |
Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
Lucy Scientific Discovery Inc | 16.73k | -9.76m | 1.46m | -- | -- | 17.96 | -- | 87.14 | -6.34 | -7.21 | 0.0103 | 0.046 | 0.0037 | -- | 0.7276 | -- | -215.45 | -- | -- | -- | 49.97 | -- | -58,360.55 | -- | -- | -5.10 | 0.4615 | -- | -- | -- | -53.49 | -- | -- | -- |
Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.48m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
180 Life Sciences Corp | 0.00 | -16.24m | 1.53m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.54m | 10.00 | -- | 0.4232 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
Finch Therapeutics Group Inc | 0.00 | -16.28m | 1.55m | 18.00 | -- | 0.0816 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
InVitro International | 716.89k | 6.22k | 1.57m | 16.00 | 197.34 | 2.15 | -- | 2.19 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
Target Group Inc | 5.64m | 228.87k | 1.57m | 46.00 | 19.62 | -- | 1.48 | 0.279 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
Procyon Corp | 4.77m | -387.79k | 1.62m | 17.00 | -- | 0.764 | -- | 0.3397 | -0.0478 | -0.0478 | 0.5891 | 0.2774 | 1.39 | 1.94 | 9.60 | 280,817.70 | -10.81 | 3.52 | -13.69 | 4.23 | 78.01 | 73.30 | -7.78 | 2.52 | 2.22 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
Dermata Therapeutics Inc | 0.00 | -8.69m | 1.70m | 8.00 | -- | 6.71 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 18.36k | 2.15% |
Tower Research Capital LLCas of 31 Mar 2024 | 3.44k | 0.40% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 750.00 | 0.09% |
BlackRock Financial Management, Inc.as of 31 Mar 2024 | 22.00 | 0.00% |
RBC Dominion Securities, Inc.as of 31 Mar 2024 | 11.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
Semmax Financial Advisors, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |